Abstract
RAC 3, one of the p160 family of co-activators is known to enhance the transcriptional activity of a number of steroid receptors. As co-activators are also known to enhance androgen receptor (AR) activity, we investigated the role of RAC 3 in the context of prostate cancer. In prostate cancer cell lines, we found variable levels of the RAC 3 protein with highest expression seen in AR-positive LNCaP cells, moderate expression in AR-negative PC 3 cells and low-level expression in AR-negative DU 145 cells. Immuno-precipitation studies showed that endogenous RAC 3 interacted with the AR in vivo and transfection assays confirmed that RAC 3 enhanced AR transcriptional activity. In clinical prostate tissue, we found strong RAC 3 mRNA expression and immuno-histochemistry demonstrated that in benign tissue, the protein was expressed predominantly in luminal cells, while in primary malignant epithelium it was more homogeneously expressed. In a series of 37 patients, the levels of RAC 3 expression correlated significantly with tumour grade (P = 0.01) and stage of disease (P = 0.03) but not with serum PSA levels. In addition moderate or high RAC 3 expression was associated with poorer disease-specific survival (P = 0.03). We conclude that RAC 3 is an important co-activator of the AR in the prostate and may have an important role in the progression of prostate cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aarnisalo P, Palvimo JJ and Janne OA (1998) CREB-binding protein in androgen receptor mediated signaling. Proc Natl Acad Sci USA 95: 2122–2127
Alen P, Claessens F, Schoenmakers E, Swinen JV, Verhoeven G, Rombauts W and Peeters B (1999) Interaction of the putative androgen receptor specific co-activator ARA70/ELE 1 α with multiple steroid receptors and identification of an internally deleted ELE 1 β isoform. Mol Endo 13: 117–128
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan X-Y, Sauter G, Kallioniemi O-P, Trent JM and Meltzer PS (1997) AIB 1, a steroid receptor co-activator amplified in breast and ovarian cancer. Science 277: 965–968
Azorsa DO and Meltzer PS (1999) Production and characterization of monoclonal antibodies to the steroid receptor co-activator AIB 1. Hybridoma 18: 281–287
Bautista S, Valles H, Walker RL, Anzick SL, Zeillinger R, Meltzer PS and Theillet C (1998) In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 4: 2925–2929
Berns EMJJ, van Staveren IL, Klijn JGM and Foekens JA (1998) Predictive value of SRC–1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res and Treat 48: 87–92
Bonkhoff H, Fixemer T, Hunsicker I and Remberger K (1999) Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 155: 641–647
Borrow J, Stanton VP, Andresen JM, Becher R, Behm FG, Chaganti RSK, Civin CI, Disteche C, Dube I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE and Housman DE (1996) The translocation t(8;16)(p11:p13) of acute myeloid leukemia fuses a putative acetyltransferase to the CREB binding protein. Nature Gen 14: 33–41
Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE and Robson CN (1999) Tip60 is a nuclear hormone receptor co-activator. J Biol Chem 274: 17599–17560
Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB and Jensen RH (1996) Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelo-typing. Cancer Res 56: 3091–3102
Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV and Bartsch G (1993) DNA sequence of the androgen receptor in prostatic tumour cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22: 11–22
Font de Mora J and Brown M (2000) AIB 1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20, (14): 5041–5047
Fujimoto N, Mizokami A, Harada S and Matsumoto T (2001) Different expression of androgen receptor co-activators in human prostate. Urology 58: 289–294
Ghadimi BM, Schrock E, Walker RL, Wangsa D, Jauho A, Meltzer PS and Reid T (1999) Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor co-activator gene in pancreatic carcinomas. Am J Path 154: 525–536
Gregory CW, Sharief Y, Hamil KG, Hall SH, Pretlow TG, Mohler JL and French FS (1995) Apoptosis in an androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Mol Biol Cell 6: 1438(abstract)
Hassig CA and Schreiber SL (1997) Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1: 300–308
Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H and Hittmair A (1996) Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28: 129–135
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS and Tung LS (1996) Nuclear receptor co-activators and co-repressors. Mol Endo 10: 1167–1177
Kang HY, Yeh S, Fujimoto N and Chang C (1999) Cloning and characterization of human prostate co-activator ARA 54, a novel protein that associates with the androgen receptor. J Biol Chem 274: 8570–8576
Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleujens K, Noordzij A, Visakorpi T and Kallioniemi OP (1997) Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314–319
Lau KM, La Spina M, Long J and Ho SM (2000) Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60: 3175–3182
Li H and Chen JD (1998) The Receptor Associated Co-activator 3 activates transcription through CREB binding protein recruitment and autoregulation. J Biol Chem 273: 5948–5954
Li H, Gomes P and Chen JD (1997) RAC 3, a steroid/nuclear receptor-associated co-activator that is related to SRC 1 and TIF 2. Proc Natl Acad Sci USA 94: 8479–8484
Meyer ME, Gronemeyer H, Turcotte B, Bocquel M-T, Tassest D and Chambon P (1989) Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 57: 433–442
Meyer ME, Quirin-Sricker C, Lerouge T, Bocquel M-T and Gronemeyer H (1992) A limiting factor mediates the differential activation of promoters by the human progesterone receptor isoforms. J Biol Chem 267: 10882–10887
Miyamato H, Yeh S, Wilding G and Chang C (1998) Promotion of agonist activity of antiandrogens by the androgen receptor co-activator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95: 7379–7384
Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R and Schule R (2000) FHL2, a novel tissue specific coactivator of the androgen receptor. EMBO J 19: 359–369
Nessler-Menardi C, Jotova I, Culig Z, Eder I, Putz T, Bartsch G and Klocker H (2000) Expression of androgen receptor coregulatory proteins in prostate cancer and stromal cell culture models. Prostate 45: 124–131
Peterziel H, Mink S, Schonert A, Becker M, Klocker H and Cato ACB (1999) Rapid signaling by androgen receptor in prostate cancer cells. Oncogene 18: 6322–6329
Sadi MV, Walsh PC and Barracks ER (1991) Immuno-histochemical study of androgen receptors in metastatic prostate cancer-comparison of receptor content and response to hormonal therapy. Cancer 67: 3057–3064
Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, Kimura A, Makamura Y, Inazawa J, Abe T and Yamagishi H (2000) Amplification and over-expression of the AIB1 nuclear receptor in primary gastric cancers. Int J Cancer 89: 217–223
Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran E, Berger SL and Halazonetis TD (1997) CREB-binding protein and p300/CBP-associated factor are transcriptional co-activators of the p53 tumour suppressor protein. Cancer Res 57: 3693–3696
Tan JA, Hall SH, Petrusz P and French FS (2000) Thyroid receptor activator molecule, TRAM–1, is an androgen receptor co-activator. Endocrinology 141, (9): 3440–3450
Tikkanen MK, Carter DJ, Harris AM, Le HM, Azorsa DO, Meltzer PS and Murdoch FE (2000) Endogenously expressed estrogen receptor and coactivator AIB1 interact in MCF-7 human breast cancer cells. Proc Natl Acad Sci USA 97: 12536–12540
Van der Kwast TH, Schalken J, Ruizveld de Winter JA, van Vroohoven CCJ, Mulder E, Boersma W and Trapman J (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189–193
Wadgoanker R and Collins T (1999) Murine Double minute (MDM 2) blocks p53 co-activator interaction, a new mechanism for inhibition of p53 dependent gene expression. J Biol Chem 274: 13760–13767
Wadgoanker R, Phelps KM, Haque Z, Williams AJ, Silverman ES and Collins T (1999) CREB binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J Biol Chem 274: 1879–1886
Wainstein MA, He F, Robinson D, Kung H-J, Scwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, Resnick MI, Seftel A and Pretlow TG (1994) CWR22:Androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 54: 6049–6052
Werbajh S, Nojek I, Lanz R and Costas MA (2000) RAC 3 is a NF-κB co-activator. FEBS Letter 485: 195–199
Wilson CM and McPhaul MJ (1994) A and B isoforms of the androgen receptor are present in human genital skin fibroblasts. Proc Natl Acad Sci USA 91: 1234–1238
Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ and O’Malley BW (1998) Partial hormone resistance in mice with disruption of the steroid receptor co-activator–1 (SRC–1) gene. Science 279: 1922–1925
Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng CHUXIA and O’Malley BW (2000) The steroid receptor co-activator SRC-3 (p/CIP/RAC 3/ AIB 1/ACTR/TRAM–1) is required for normal growth, puberty, female reproductive function and mammary gland development. Proc Natl Acad Sci USA 97, (12): 6379–6384
Yeh S and Chang C (1996) Cloning and characterization of a specific co-activator, ARA70 for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93: 5517–5521
Yeh S, Miyamato H, Shima H and Chang C (1998) From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 95: 5527–5532
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Gnanapragasam, V., Leung, H., Pulimood, A. et al. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85, 1928–1936 (2001). https://doi.org/10.1054/bjoc.2001.2179
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2179
Keywords
This article is cited by
-
ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer
Nature Communications (2022)
-
The Role of Steroid Receptor Coactivators in Hormone Dependent Cancers and Their Potential as Therapeutic Targets
Hormones and Cancer (2016)
-
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
Hormones and Cancer (2016)
-
Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis
International Journal of Clinical Oncology (2014)
-
Androgen receptor signaling in prostate cancer
Cancer and Metastasis Reviews (2014)